About the CardioMEMS HF System
The CardioMEMS™ HF System allows clinicians to monitor heart failure patients’ pulmonary artery (PA) pressure for proactive and actionable heart failure (HF) management and treatment. With early indications of worsening heart failure, you can remotely make adjustments to care to help slow the progression of heart failure, often before patients feel symptoms.
Abbott’s CardioMEMS HF System is the leading remote monitoring platform for both HFpEF1 and HFrEF patients clinically proven to:
- Aid physicians in preventing worsening heart failure2
- Lower heart failure mortality rates3
- Improve quality of life for heart failure patients4
CardioMEMS HF System Product Information
Indications
The CardioMEMS HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.
Contraindications
The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.
CardioMEMS HF System Clinical Evidence
Multiple clinical trials have evaluated the safety and effectiveness of the CardioMEMS HF System. For a deep dive into the clinical studies and trial designs, view more information on the Clinical Evidence.
Key Clinical Outcomes
Improved Survival4-6
Reduction in Heart Failure Hospitalizations for HFpEF and HFrEF Patients7
Outstanding Safety Data
More about the CardioMEMS HF System
For safe and reliable HF management with the CardioMEMS HF System, we provide comprehensive educational resources. The following are designed to help you and your patients better understand patient selection, implantation and care.
References
- Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure. 2014;7(6):935-944.
- Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Current Heart Failure Reports. 2009;6:287-292.
- Abraham J, et al. Association of Ambulatory Hemodynamic Monitoring with Clinical Outcomes in a Concurrent Matched Cohort Analysis. JAMA Cardiology. 2019;4(6):556-563.
- Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, for the CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet. 2016;387(10017):453-461.
- Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G, Abraham WT; CHAMPION Trial Investigators. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2017.
- JoAnn Lindenfeld, on behalf of the GUIDE-HF, CHAMPION, and LAPTOPHF investigators. Longer Term Effects of Hemodynamic Monitoring on Outcomes: A Combined Data Analysis of patients with HFrEF in CHAMPION, GUIDE-HF, and LAPTOP-HF. Presented at THT Conference, Boston, MA, March 2023.
- Shavelle D. et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure. Circulation: Heart Failure. Advance online publication. https://doi.org/10.1161/circheartfailure.119.006863.
MAT-2006904 v6.0
Stay Connected